Capricor Therapeutics (CAPR) Misses Q2 EPS by 2c

Capricor Therapeutics (NASDAQ: CAPR) reported Q2 EPS of ($0.26), $0.02 worse than the analyst estimate of ($0.24).

For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.

You May Also Be Interested In

• UBS says bull market has further to run
• Ubiquiti (UI) Tops Q4 EPS by 25c, Beats on Revenue
• Redwood Trust (RWT) PT Lowered to $6.50 at UBS Amid Legacy Portfolio Wind-Down